TY - JOUR
T1 - Correction to Lancet Gastroenterol Hepatol 2022; 7
T2 - 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))
AU - Danese, Silvio
AU - Vermeire, Severine
AU - D'Haens, Geert
AU - Panés, Julian
AU - Dignass, Axel
AU - Magro, Fernando
AU - Nazar, Maciej
AU - Le Bars, Manuela
AU - Lahaye, Marjolein
AU - Ni, Lioudmila
AU - Bravata, Ivana
AU - Lavie, Frederic
AU - Daperno, Marco
AU - Lukáš, Milan
AU - Armuzzi, Alessandro
AU - Löwenberg, Mark
AU - Gaya, Daniel R.
AU - Peyrin-Biroulet, Laurent
AU - STARDUST study group
AU - Rocca, Rodolfo
AU - Lopes, Susana
AU - Caprioli, Flavio
AU - Ardizzone, Sandro
AU - Echarri Piudo, Ana
AU - Gionchetti, Paolo
AU - Roblin, Xavier
AU - Seidler, Ursula
AU - Andersson, David
AU - Patel, Kamal
AU - Desreumaux, Pierre
AU - Saibeni, Simone
AU - From, Gustav
AU - Fedurco, Miroslav
AU - Gregus, Milos
AU - Bouhnik, Yoram
AU - Luegering, Andreas
AU - Cosintino, Rocco
AU - Bunganic, Ivan
AU - Ramos, Jaime
AU - Aguas Peris, Mariam
AU - Dewit, Olivier
AU - Principi, Mariabeatrice
AU - Wesley, Emma
AU - Lago, Paula
AU - Nancey, Stephane
AU - Martín Arranz, María Dolores
AU - Hindryckx, Pieter
AU - Orlando, Ambrogio
AU - Geccherle, Andrea
AU - Annunziata, Maria Laura
A2 - Mowat, Craig
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.
AB - Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.
UR - http://www.scopus.com/inward/record.url?scp=85125879717&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(22)00055-3
DO - 10.1016/S2468-1253(22)00055-3
M3 - Article
C2 - 35278403
SN - 2468-1253
VL - 7
SP - e8
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 4
ER -